PQQ Dosage: What the Trials Used (10–40mg) vs. What's on the Shelf
Educational summary — not medical advice. PQQ has no established RDA or upper limit, and no long-term (6-month+) human safety data at any dose. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
Human trials used 10–21.5 mg/day, and 20 mg/day is both the single most-used trial dose (5 of 12 trials) and the most common retail dose — a rare alignment for this site's supplement clusters. The largest trial (Shiojima 2022, n=58) used 21.5 mg/day, but of a different branded ingredient (mnemoPQQ, not BioPQQ). Retail products range roughly 10–40 mg per serving — the 10mg and 40mg tiers exist without a matching human trial at exactly those doses. No human trial here has tested above about 22 mg/day. There's no RDA or upper limit because PQQ isn't an essential nutrient.
The 20mg alignment, and where retail overshoots the evidence
PQQ's dosage story is unusually tidy compared to this site's other longevity-adjacent clusters. NMN's most-studied dose (250mg) is a fraction of what some retail products sell (up to 1200mg), and spermidine's retail doses frequently run 8-12× above the trial range. PQQ doesn't have that gap at its most common dose: 20mg/day is what five of the twelve verified trials used — Itoh/Nakano 2016 (Stroop-attention improvement), Nakano 2016 (cerebral blood flow), Nakano 2015 (cholesterol, subgroup-driven), Tamakoshi 2023 (memory, age-split), and Hwang 2020 (PGC-1α biomarker, no functional benefit) — and it's also the dose on most retail labels, including all three pure products tracked in this comparison. The one trial that pushed higher, Shiojima 2022, used 21.5mg/day of mnemoPQQ®, a different branded ingredient than BioPQQ™ — so it isn't evidence that 21.5mg of a BioPQQ product would do the same thing. Where retail does outrun the evidence is at the edges: 10mg products exist below any dose a trial has tested, and 40mg products exist roughly double the highest dose any human trial has used, with zero efficacy or safety data at that level. Neither extreme has trial support; the honest default is the well-studied middle.
| Use case | Dose studied | Result |
|---|---|---|
| Most-studied single dose | 20 mg/day, 6-12 weeks | Attention/Stroop improvement, cerebral blood flow rise, subgroup cholesterol reduction, age-split memory gains, PGC-1α biomarker rise with no functional benefit — 5 trials, all BioPQQ, all Mitsubishi-Gas-Chemical-affiliated except Hwang |
| Largest completer-n trial | 21.5 mg/day, 12 weeks | Broad cognitive-domain improvement (Cognitrax) — different branded ingredient (mnemoPQQ), Cepham-affiliated senior author, not a BioPQQ replication |
| Retail floor | 10 mg/day | No dedicated human trial at exactly this dose |
| Retail ceiling | 40 mg/day | Roughly double the highest human-tested dose (Shiojima's 21.5mg); no efficacy or safety data at this level in any trial |
Dose checker: how much PQQ are you actually taking?
Enter the PQQ milligrams per serving from your label (look for "PQQ ___ mg" on the Supplement Facts panel) and how many servings you take per day.
How to think about dose
- 20 mg/day is the best-supported default — it's the dose with the most trials behind it (5 of 12) and the most common retail dose, a rare alignment on this site.
- 21.5 mg/day (Shiojima's dose) is not a BioPQQ target. It's the largest trial here, but on a different branded ingredient (mnemoPQQ) — don't treat it as "the next dose up" from 20mg of a BioPQQ product.
- 40 mg retail products have no trial support at all. That's roughly double the highest dose any human PQQ trial has tested, in any form.
- Oral rat toxicology margins are wide (100-400mg/kg/day NOAELs) but that's animal data, not license to take a much higher human dose than any trial has tested — see the hub for the full kidney-safety framing.
- Pregnant or breastfeeding? There is no data at all for PQQ in this population — check with a clinician, because of the total absence of data, not a specific toxicity signal.
Picks by dose
Full ranking, including the BioPQQ-branded vs. generic-disodium tiers (the primary axis for PQQ), is on best PQQ.
Discloses 20 mg per serving — matches the most-used human trial dose.
Names BioPQQ™ specifically — the raw material used in most of the cited trials.
As an Amazon Associate we earn from qualifying purchases. Of 3 pure-PQQ products tracked; ranked by disclosed mg, never commissions.
Frequently asked questions
How much PQQ should I take per day?
20mg/day is both the most-used trial dose (5 of 12 trials) and the most common retail dose. The largest trial (21.5mg, Shiojima 2022) used a different ingredient. No trial has tested above ~22mg/day.
Is a higher PQQ dose better?
Not shown by any trial. No human trial has tested above 21.5mg/day — retail products at 40mg have zero efficacy or safety data at that level.
Is PQQ safe at typical doses?
Yes, well tolerated up to 21.5mg/day for 12 weeks in every trial. Oral rat NOAELs (100-400mg/kg/day) offer a wide margin, but no long-term human data exists at any dose.
Is there a PQQ RDA or upper limit?
No. Not an essential nutrient, so no RDA or official UL exists. Trial doses (10-21.5mg) and retail range are reference points, not regulatory limits.
Related
- PQQ: what it is & who it's for
- Best PQQ — BioPQQ-branded vs. generic disodium, ranked
- PQQ for memory & cognitive function
- Does PQQ actually work?
Sources
- Itoh Y, Nakano M, et al. 2016. Adv Exp Med Biol. PMID: 26782228 (20 mg/day).
- Nakano M, et al. 2016. Adv Exp Med Biol. PMID: 27526146 (20 mg/day).
- Nakano M, et al. 2015. J Nutr Sci Vitaminol. PMID: 26226960 (20 mg/day).
- Tamakoshi M, et al. 2023. Food Funct. PMID: 36807425 (20 mg/day).
- Hwang PS, et al. 2020. J Am Coll Nutr. PMID: 31860387 (20 mg/day).
- Shiojima Y, Bagchi D, et al. 2022. J Am Nutr Assoc. PMID: 34415830 (21.5 mg/day, different branded ingredient).
- Full product dataset: /pqq/cost-by-brand.json (CC BY 4.0).